The Integrated Forecasting and Analysis Tool   Login Now

Watson Pharmaceuticals

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Watson Pharmaceuticals are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Watson Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

Annual Sales WW - Sales Growth per Year (%)   Rank Product Generic Name Pharmacological Class 2006 2007 2007 Watson Pharmaceuticals 1 Ferrlecit ferric gluconate Iron supplement 141 136   (3%)     2 Hydrocodone / Acetaminophen acetaminophen & hydrocodone Narcotic analgesic & non-narcotic analgesic 113 120   7%     3 Bupropion bupropion Noradrenaline & dopamine reuptake inhibitor 73 67   (8%)       Note: Shaded Cells

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) Watson Pharmaceuticals 1 Silodosin Genito-Urinary Prostatic therapies Alpha 1 antagonist Filed   2 Methylphenidate XR Central Nervous System Psychostimulants Psychostimulant Filed   3 Fluticasone propionate Respiratory Corticoids Corticosteroid Filed

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Watson Pharmaceuticals   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 2,865 2,865        PE Ratio (diluted) - Normalised (x) 20.3 29.7        Valuing the Enterprise        Enterprise Value 3,554 3,554        Free Cash Flow (Pre-Dividends) 253 462        FCF Yield (%) 7.1% 13.0%    Forecast Financials   Income Statement      Total Revenues 1,646 1,979      Cost of Goods Sold (852) (1,233)      S,G & A (261) (305)      R&D (125) (131)      Other Income/ Expense - Net (167) (143)      EBIT - Normalised 241 167      Net Interest & Financial Items 5 6      Pre-tax Profits - Normalised 245 173      Exceptionals (25) (584)      Income Before Taxes 220 (411)      Tax (81) (34)      Tax Rate (%) 37.0% 8.3%      Net Income - Reported 139 (445)      Net Income - Normalised 155 107     Per Share Data      EPS - Diluted 1.22 (3.82)      EPS - Basic 1.32 (4.37)      EPS - Normalised (diluted) 1.35 0.92      EPS - Normalised (basic) 1.47 1.06      Avg. Shares Outstanding - Diluted 120.0 116.4      Avg. Shares Outstanding - Basic 104.9 101.8      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules   (Watson Pharmaceuticals)   03-Jun-2008 Watson Receives Final Approval of Omeprazole Delayed-Release Capsules   (Watson Pharmaceuticals)   02-Jun-2008 Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder   (Watson Pharmaceuticals)   28-May-2008 Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder   (Watson Pharmaceuticals)   21-May-2008 FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA   (Watson Pharmaceuticals)   30-Apr-2008 Watson Files FDA Application for Generic FENTORA(R)   (Watson Pharmaceuticals)   24-Apr-2008 Cephalon Notified of Generic Fentanyl Buccal Tablet Filing   (Cephalon)   24-Apr-2008 Watson Files FDA Application for Generic YASMIN(R)   (Watson Pharmaceuticals)   21-Apr-2008 Watson Files FDA Application for Generic LYBREL(R)   (Watson Pharmaceuticals)   13-Mar-2008 Watson Files Application for Generic SEASONIQUE(R)   (Watson Pharmaceuticals)   04-Mar-2008 New Drug Application for Silodosin   (Kissei Pharmaceutical)   13-Feb-2008 Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia   (Watson Pharmaceuticals)   12-Feb-2008 Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer   (Debiopharm)   12-Feb-2008 Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder   (Watson Pharmaceuticals)   07-Jan-2008 Watson Launches Generic Biaxin(R) XL   (Watson Pharmaceuticals)   03-Jan-2008 Watson Receives FDA Approval for Generic DuoNeb(R)   (Watson Pharmaceuticals)   02-Jan-2008 Salix Announces Launch of COLAZAL® Authorized Generic with Watson   (Salix Pharmaceuticals)   28-Dec-2007 Watson Receives FDA Approval For Generic Combunox(R)   (Watson Pharmaceuticals)   27-Nov-2007 Watson Files FDA Application for Generic YAZ(R)   (Watson Pharmaceuticals)   07-Nov-2007 Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe   (Watson Pharmaceuticals)   29-Oct-2007 Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe   (Warner Chilcott)   29-Oct-2007 Watson Files Application for Generic FEMCON(R) Fe   (Watson Pharmaceuticals)   03-Oct-2007 Watson Receives FDA Approval for Generic AccuNeb(R)   (Watson Pharmaceuticals)   26-Sep-2007 Watson Receives FDA Approval For Generic Duragesic(R)   (Watson Pharmaceuticals)   21-Aug-2007 Ranbaxy Receives US FDA Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP   (Ranbaxy Laboratories)   20-Aug-2007 Watson Receives FDA Final Approval for Generic Wellbutrin XL(R) 300 Mg   (Watson Pharmaceuticals)   13-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Watson Pharmaceuticals Acetaminophen & codeine phosphate acetaminophen & codeine   Actigall ursodiol   ACTOplus met XR pioglitazone & metformin   Albuterol Inhalation Aerosol albuterol   Albuterol Sulfate albuterol   Alendronate alendronate sodium   Alora estradiol   Altoprev lovastatin   Androderm testosterone   AndroGel testosterone   Anexsia acetaminophen & hydrocodone   BACC butalbital, aspirin, caffeine & codeine   Benazepril hydrochloride benazepril   Bisoprolol fumarate/hydrochlorothiazide bisoprolol & hydrochlorothiazide   Brevicon ethinyl estradiol & norethindrone   Bupropion bupropion   Buspirone buspirone   Carisoprodol carisoprodol   Cartia XT diltiazem   Cefuroxime Axetil cefuroxime axetil   Cilostazol cilostazol   Cinobac cinoxacin   Citalopram citalopram   Clarithromycin ER clarithromycin   Cleocin T clindamycin   Clomipramine clomipramine   Clopidogrel clopidogrel   Clorazepate clorazepate   Colazal balsalazide   Condylox podophyllotoxin   Contraception patch -   Cordran flurandrenolide   Cormax clobetasol propionate   Cyclobenzaprine cyclobenzaprine hydrochloride   Desogestrel & Ethinyl Estradiol desogestrel & ethinyl estradiol   Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate & Amphetamine Sulfate dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate & amphetamine sulfate   Dicyclomine dicyclomine   Dilacor XR diltiazem   Diltiazem ER diltiazem   Doxazosin Mesylate doxazosin   Drospirenone & Ethinyl estradiol ethinyl estradiol & drospirenone   Eldepryl selegiline   Embrex multivitamin & calcium   Emsam selegiline   Enalapril Maleate enalapril   Enoxaparin Sodium enoxaparin   Entex guaifenesin & phenylpropanolamine   Estradiol estradiol   Estradiol & Progesterone estradiol & progesterone   Estropipate estropipate   Ethinyl estradiol & levonorgestrel (Levlite) ethinyl estradiol & levonorgestrel   Ethinyl estradiol & levonorgestrel (Lybrel) ethinyl estradiol & levonorgestrel   Ethinyl estradiol & levonorgestrel (Seasonique) ethinyl estradiol & levonorgestrel   Etodolac etodolac   Famotidine famotidine   Fentanyl Buccal Tablets C-II fentanyl   Fentanyl Citrate fentanyl   Fentanyl lozenge fentanyl   Fentanyl Transdermal fentanyl   Ferrlecit ferric gluconate   Fioricet butalbital, acetaminophen & caffeine   Fiorinal butalbital, aspirin & caffeine   Fluoxetine fluoxetine   Fluticasone propionate fluticasone propionate   Fortamet metformin   Fosinopril fosinopril   Furosemide furosemide   Glipizide ER glipizide   Guanfacine guanfacine   Hydrocodone & Ibuprofen hydrocodone & ibuprofen   Hydrocodone / Acetaminophen acetaminophen & hydrocodone   Hydroxychloroquine hydroxychloroquine sulfate   Hydroxyzine hydroxyzine   Ibuprofen & Oxycodone ibuprofen & oxycodone   INFed iron dextran   Intrinsa testosterone   Ipratropium & Albuterol ipratropium & albuterol   Jolivette norethindrone   Ketoprofen ER ketoprofen   Levora ethinyl estradiol & levonorgestrel   Lisinopril lisinopril   Lisinopril & HCTZ lisinopril & hydrochlorothiazide   Loratadine & Pseudoephedrine loratadine & pseudoephedrine   Loratadine orally disintegrating tablets loratadine   Lorazepam lorazepam   Lovastatin lovastatin   Low-Ogestrel ethinyl estradiol & norgestrel   Loxapine succinate loxapine   Loxitane loxapine   Lutera ethinyl estradiol & levonorgestrel   Maxidone acetaminophen & hydrocodone   Meprobamate meprobamate   Metformin metformin   Metformin & Glyburide metformin & glyburide   Metformin XR metformin   Methocarbamol methocarbamol   Methylphenidate hydrochloride methylphenidate   Methylphenidate XR methylphenidate   Metoprolol Succinate metoprolol succinate   Microgestin ethinyl estradiol & norethindrone acetate   Microzide hydrochlorothiazide   Minocycline minocycline   Mirtazapine mirtazapine   Monodox doxycycline   MonoNessa ethinyl estradiol & norgestimate   Morphine QD morphine sulfate   Morphine sulphate morphine sulfate   Naproxen Sodium naproxen   Necon ethinyl estradiol & norethindrone   Necon 7/7/7 ethinyl estradiol & norethindrone acetate   Nefazodone nefazodone   Nicotine polacrilex gum nicotine polacrilex   Nicotine transdermal system nicotine   Nifedipine ER nifedipine   Nitrofurantoin nitrofurantoin monohydrate   Nizatidine nizatidine   Nora-BE norethindrone   Norco acetaminophen & hydrocodone   Norinyl ethinyl estradiol & norethindrone   Nor-QD norethindrone   Ogestrel ethinyl estradiol & norgestrel   Onychomycosis patch -   Oxandrolone oxandrolone   Oxaprozin oxaprozin   Oxycodone oxycodone   Oxycodone & acetaminophen acetaminophen & oxycodone   Oxytrol oxybutynin   Paroxetine paroxetine   Pemoline pemoline   Pentazocine & Naloxone pentazocine & naloxone   Pentazocine with APAP pentazocine & acetaminophen   Pentoxifylline (Trental) pentoxifylline   Pioglitazone pioglitazone   Potassium Chloride potassium chloride   Pravastatin pravastatin   Prestara prasterone   Promethazine promethazine   Propafenone propafenone   ProQuin XR ciprofloxacin   PT-14 -   Pyridostigmine Bromide pyridostigmine bromide   Quasense ethinyl estradiol & levonorgestrel   Quinapril quinapril   Ranitidine ranitidine   Reprexain hydrocodone & ibuprofen   Rivastigmine rivastigmine   Silodosin silodosin   Sotalol sotalol   Sucralfate sucralfate   Sulfasalazine sulfasalazine   Sulindac sulindac   Tamoxifen tamoxifen   Taztia XT diltiazem   Terconazole terconazole   Testosterone gel testosterone   Tilia ethinyl estradiol & norethindrone   Tramadol tramadol   Trazodone trazodone   Trelstar triptorelin   Trihexyphenidyl HCl trihexyphenidyl   Trinessa ethinyl estradiol & norgestimate   Tri-Norinyl ethinyl estradiol & norethindrone   Trivora ethinyl estradiol & levonorgestrel   Unithroid levothyroxine   Uracyst sodium chondroitin sulfate   Valacyclovir valacyclovir   Zalkote valproate sodium   Zenchent ethinyl estradiol & norethindrone   Zovia ethinyl estradiol & ethynodiol diacetate

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 14:24:54 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd